glp-1 news oct 21 2025 Top Agonists Balance Weight Loss Efficacy, Safety Beyond glycemia: Comparing tirzepatide Quantity:6 Months Health

glp-1 news oct 21 2025 Top Agonists Balance Weight Loss Efficacy, Safety Beyond glycemia: Comparing tirzepatide Quantity:6 Months Health

Beyond glycemia: Comparing tirzepatide to GLP-1 analogues - PMC

These physiological effects make GLP-1 a highly attractive target for managing type 2 diabetes and obesity

Health

Quantity:6 Months

Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years News provided by Prime Therapeutics LLC Jun 25, 2025, 10:00 ET Findings also show improved persistence with high-potency, obesity-approved GLP-1 products EAGAN, Minn., June 25, 2025 /PRNewswire/ -- Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from pharmacy solutions partner Prime Therapeutics LLC (Prime)